Picture of Entrada Therapeutics logo

TRDA — Entrada Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousSmall CapSucker Stock

Entrada Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

* Entrada Therapeutics Inc  TRDA.OQ  reported a quarterly
adjusted
loss of 29 cents​​ per share for the quarter ended in December,
higher than the same quarter last year, when the company
reported EPS of -79 cents.  The mean expectation of
five analysts for the quarter was for a loss of 17 cents per
share. Wall Street expected results to range from -53 cents
to 21 cents per share.
    * Revenue was $41.85 million​; analysts expected $23.70
million. 
    * Entrada Therapeutics Inc's reported EPS for the quarter
was a
loss of 29 cents​.
    * The company reported a quarterly loss of $9.54 million.
    * Entrada Therapeutics Inc shares had fallen by 23.3% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 30% in
the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is  "buy."

Wall Street's median 12-month price target for Entrada
Therapeutics Inc is $21.00 
This summary was machine generated from LSEG data March 13 at
12:37 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.17          -0.29          Missed
 Sep. 30 2023      -0.74          1.02           Beat
 Jun. 30 2023      -0.69          -0.78          Missed
 Mar. 31 2023      0.97           -0.21          Missed

Recent news on Entrada Therapeutics

See all news